Meta Information
ID:retatrutide
Name:
Schema Version:AIM-2.0
Interactions
Target id:
/class/antidiabetic-medications
Target name:
Other Diabetes Medications (especially Insulin or Sulfonylureas)
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Retatrutide potently lowers blood glucose, and combining it with other glucose-lowering drugs like insulin or sulfonylureas significantly increases the risk of severe hypoglycemia (dangerously low blood sugar).
Actionable advice:
Your doctor must review and likely reduce the dosage of your other diabetes medications when starting Retatrutide.
Target id:
/class/glp-1-receptor-agonists
Target name:
Other GLP-1 Receptor Agonists (e.g., Semaglutide, Liraglutide)
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Using Retatrutide with other GLP-1 agonists is duplicative therapy, as they share a mechanism of action. This combination has not been studied and would significantly increase the risk and severity of gastrointestinal side effects.
Actionable advice:
Avoid using Retatrutide concurrently with any other GLP-1 receptor agonist medication.
Target id:
/intervention/tirzepatide
Target name:
Tirzepatide
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Using Retatrutide with Tirzepatide is duplicative therapy, as they share both the GLP-1 and GIP receptor agonist mechanisms. This combination would lead to an excessive and unstudied level of incretin stimulation, increasing side effect risks.
Actionable advice:
Do not use Retatrutide and Tirzepatide at the same time.
Target id:
/condition/medullary-thyroid-carcinoma-history
Target name:
Personal or Family History of Medullary Thyroid Carcinoma (MTC) or MEN 2
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
In animal studies, drugs in this class caused thyroid C-cell tumors. It is unknown if this risk applies to humans, but as a precaution, it is contraindicated in individuals with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Actionable advice:
Avoid completely if you or a family member has a history of MTC or MEN 2.
Target id:
/condition/gastroparesis
Target name:
Gastroparesis (Delayed Gastric Emptying)
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Retatrutide's mechanism involves slowing down stomach emptying. In individuals with pre-existing gastroparesis, this effect would worsen the condition, potentially leading to severe nausea, vomiting, and malnutrition.
Actionable advice:
Avoid completely if you have a diagnosis of moderate to severe gastroparesis.
Target id:
/condition/pregnancy
Target name:
Pregnancy
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
There is no data on the use of Retatrutide in pregnant women, and significant weight loss is not recommended during pregnancy. Potential fetal harm cannot be ruled out.
Actionable advice:
Avoid completely if you are pregnant or planning to become pregnant.
Target id:
/condition/lactation
Target name:
Breastfeeding (Lactation)
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
It is not known whether Retatrutide passes into human breast milk. Due to the potential for adverse effects in a nursing infant, its use is not recommended.
Actionable advice:
Avoid completely while breastfeeding.
Target id:
/procedure/surgery-anesthesia
Target name:
Surgery with General Anesthesia
Severity:
major
Interaction type:
adverse
Nature:
temporal
Temporal spacing:
Hours before target:
168
Hours after target:
null
Description:
Retatrutide delays gastric emptying, which increases the risk of regurgitation and aspiration of stomach contents into the lungs during anesthesia. This can cause serious complications.
Actionable advice:
Inform your surgeon that you take Retatrutide; it should be stopped at least one week before elective surgery.
Target id:
/class/oral-medications-general
Target name:
All Orally Administered Medications
Severity:
moderate
Interaction type:
diminishing
Nature:
temporal
Temporal spacing:
Hours before target:
1
Hours after target:
4
Description:
By delaying gastric emptying, Retatrutide can slow down the absorption of any medication taken by mouth, potentially reducing its peak concentration and effectiveness.
Actionable advice:
Take oral medications at least 1 hour before or 4+ hours after your largest meal of the day to minimize absorption impact.
Target id:
/class/estrogens
Target name:
Oral Contraceptives
Severity:
moderate
Interaction type:
diminishing
Nature:
absolute
Temporal spacing:
null
Description:
Delayed gastric emptying caused by Retatrutide can reduce the absorption rate of oral contraceptives, potentially compromising their effectiveness.
Actionable advice:
Discuss using a non-oral backup method of contraception with your doctor, especially for the first month of use.
Target id:
/condition/history-of-pancreatitis
Target name:
History of Pancreatitis
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Medications in this class have been associated with an increased risk of acute pancreatitis. The risk may be higher in individuals with a prior history of the condition.
Actionable advice:
Use with caution and immediately report any symptoms of severe, persistent abdominal pain to your doctor.
Target id:
/condition/renal-impairment
Target name:
Renal Impairment
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Severe gastrointestinal side effects like vomiting or diarrhea can lead to dehydration, which can cause or worsen kidney problems. The drug itself is not directly toxic to the kidneys.
Actionable advice:
Maintain excellent hydration, especially during dose escalation, and report any decrease in urination.
Target id:
/condition/gallbladder-disease
Target name:
Gallbladder Disease
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Rapid weight loss, a common effect of Retatrutide, is a known risk factor for developing gallstones (cholelithiasis) and gallbladder inflammation (cholecystitis).
Actionable advice:
Report any new symptoms of sharp pain in the upper right abdomen, nausea, or fever to your doctor.
Target id:
/dietary/meal
Target name:
Large, High-Fat, or High-Sugar Meals
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Because Retatrutide slows stomach emptying, consuming large or rich meals can overwhelm the digestive system, significantly worsening side effects like nausea, bloating, and reflux.
Actionable advice:
Eat smaller, more frequent, lower-fat meals to minimize gastrointestinal discomfort.
Target id:
/dietary/alcohol-acute
Target name:
Alcohol
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Alcohol can independently lower blood sugar, and when combined with Retatrutide, it can increase the risk of hypoglycemia. It can also irritate the stomach, exacerbating GI side effects.
Actionable advice:
Limit alcohol consumption and avoid drinking on an empty stomach to reduce risks.
Target id:
/dietary/water
Target name:
Fluid Intake
Severity:
moderate
Interaction type:
requirement
Nature:
absolute
Temporal spacing:
null
Description:
Adequate hydration is crucial to counteract potential fluid loss from gastrointestinal side effects (nausea, vomiting, diarrhea) and to protect kidney function.
Actionable advice:
Ensure you drink plenty of water and electrolyte-containing fluids throughout the day.
Target id:
/condition/diabetic-retinopathy
Target name:
Diabetic Retinopathy
Severity:
minor
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Rapid improvements in blood sugar control have been associated with a temporary worsening of diabetic retinopathy in some individuals. This is a known effect of potent glucose-lowering therapies.
Actionable advice:
Ensure you have regular eye exams, especially when starting or significantly changing your diabetes treatment.
Target id:
/biomarker/resting-heart-rate
Target name:
Resting Heart Rate
Severity:
minor
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Retatrutide and other GLP-1 agonists can cause a small, dose-dependent increase in resting heart rate. The clinical significance of this is generally considered low for most people.
Actionable advice:
Be aware of a potential small increase in your resting heart rate; report palpitations or a persistently high rate to your doctor.
Target id:
/biomarker/amylase-lipase
Target name:
Amylase and Lipase Levels
Severity:
minor
Interaction type:
assay_interference
Nature:
absolute
Temporal spacing:
null
Description:
Asymptomatic elevations in pancreatic enzymes (amylase and lipase) can occur with this class of medication. This is not necessarily indicative of pancreatitis without corresponding symptoms.
Actionable advice:
Do not be alarmed by minor elevations on lab tests, but report any severe abdominal pain immediately.
Target id:
/biomarker/calcitonin
Target name:
Serum Calcitonin
Severity:
minor
Interaction type:
assay_interference
Nature:
absolute
Temporal spacing:
null
Description:
Due to the theoretical risk of thyroid C-cell effects, serum calcitonin (a biomarker for MTC) may be monitored. The relevance of small changes during treatment is uncertain.
Actionable advice:
If your doctor monitors calcitonin levels, discuss the results in the context of your overall health.